Skip to Main Content
TABLE 2

Clinical characteristics in the subgroups according to the status of a 50% reduction of UAE at each follow-up period

50% reduction group
Nonreduction group
Achieved periodAbsent period
A1C (%) 7.3 ± 1.1* 7.4 ± 0.8 7.5 ± 1.0 
Blood pressure (mmHg)    
    Systolic 133 ± 16* 139 ± 16 139 ± 18 
    Diastolic 74 ± 9 76 ± 9 76 ± 10 
Cholesterol (mg/dl)    
    Total 201 ± 29 204 ± 23 205 ± 30 
    Triglycerides 97 (75–146) 104 (75–138) 110 (80–149) 
    HDL 53 ± 14 56 ± 13 53 ± 15 
BMI (kg/m223.7 ± 3.7* 24.7 ± 3.3 24.3 ± 3.3 
RAS blockade treatment (%) 48 46 43 
Lipid-lowering treatment (%) 34 32 27 
Current smoker (%) 23 28 30 
50% reduction group
Nonreduction group
Achieved periodAbsent period
A1C (%) 7.3 ± 1.1* 7.4 ± 0.8 7.5 ± 1.0 
Blood pressure (mmHg)    
    Systolic 133 ± 16* 139 ± 16 139 ± 18 
    Diastolic 74 ± 9 76 ± 9 76 ± 10 
Cholesterol (mg/dl)    
    Total 201 ± 29 204 ± 23 205 ± 30 
    Triglycerides 97 (75–146) 104 (75–138) 110 (80–149) 
    HDL 53 ± 14 56 ± 13 53 ± 15 
BMI (kg/m223.7 ± 3.7* 24.7 ± 3.3 24.3 ± 3.3 
RAS blockade treatment (%) 48 46 43 
Lipid-lowering treatment (%) 34 32 27 
Current smoker (%) 23 28 30 

Data are means ± SD for normally distributed continuous variables or median (25th–75th interquartiles) for skewed continuous variables unless otherwise indicated. In the 50% reduction group, the mean levels of systolic blood pressure and BMI at the period when a 50% reduction was achieved (achieved period) were lower than those at the period when it was not achieved (absent period). Renin-angiotensin system (RAS) blockade treatment includes ACE inhibitors and angiotensin II receptor blockers.

*

P < 0.05 vs. the nonreduction group;

P < 0.05 vs. absent period.

Close Modal

or Create an Account

Close Modal
Close Modal